Marianne De Backer, Vir Biotechnology CEO at Endpoints' JPM24 (Credit: Brian Benton Photography)

November 18, 2024 09:35 PM EST

Vir, Bluejay invigorate hepatitis D landscape with new data

Max Bayer

Pharma Reporter

New readouts of hepatitis D treatments are prompting optimism that the long-barren set of options for patients might have new options on the horizon. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Vir, Bluejay invigorate hepatitis D landscape with new data

Max Bayer

Pharma Reporter

Sign up to read this article for free.

Rocket shares promising long-term results from rare heart disease gene therapy in small study

FDA offers more guidance on developing cell and gene therapies

A rare neurological disease is Sage’s last, best hope after failures in depression

Novartis strikes radiopharma deal with Ratio worth up to $745M

Neurogene patient had life-threatening side effect in Rett syndrome study

Are programs with compounded GLP-1s safe for your population?

Vir, Blue­jay in­vig­o­rate he­pati­tis D land­scape with new da­ta

Max Bayer

Pharma Reporter

Sign up to read this article for free.

Rock­et shares promis­ing long-term re­sults from rare heart dis­ease gene ther­a­py in small study

FDA of­fers more guid­ance on de­vel­op­ing cell and gene ther­a­pies

A rare neu­ro­log­i­cal dis­ease is Sage’s last, best hope af­ter fail­ures in de­pres­sion

No­var­tis strikes ra­dio­phar­ma deal with Ra­tio worth up to $745M

Neu­ro­gene pa­tient had life-threat­en­ing side ef­fect in Rett syn­drome study

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

Vir, Bluejay invigorate hepatitis D landscape with new data

Rocket shares promising long-term results from rare heart disease gene therapy in small study

FDA offers more guidance on developing cell and gene therapies

A rare neurological disease is Sage’s last, best hope after failures in depression

Novartis strikes radiopharma deal with Ratio worth up to $745M

Neurogene patient had life-threatening side effect in Rett syndrome study

Are programs with compounded GLP-1s safe for your population?